Company profile for Duality Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases. Leveraging on the decades of learning, we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. These include DITAC (Duality Immune Toxin Antibody Conjuga...
DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases. Leveraging on the decades of learning, we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. These include DITAC (Duality Immune Toxin Antibody Conjugate) with significantly improved therapeutic window and DIMAC (Duality Immune Modulating Antibody Conjugate) with superior efficacy than traditional biologics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Unit 1105-1106, No 868 YingHua Road, Pudong New District, Shanghai
Telephone
Telephone
021-2601 8730
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate

PRESS RELEASE
06 Sep 2025

https://www.prnewswire.com/news-releases/preliminary-data-from-two-clinical-trials-with-adc-candidates-were-presented-orally-at-the-2025-asco-annual-meeting-302473942.html

PR NEWSWIRE
04 Jun 2025

https://www.prnewswire.com/news-releases/fda-clearance-of-investigational-new-drug-application-received-for-novel-egfrher3-bispecific-antibody-drug-conjugate-avzo-1418db-1418-302463934.html

PR NEWSWIRE
22 May 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-duality-biotherssapeutics-shares-set-rise-91-hong-kong-debut-2025-04-15/

REUTERS
14 Apr 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-duality-biotherapeutics-tests-market-appetite-with-200-million-hong-kong-2025-04-07/

REUTERS
07 Apr 2025

https://www.prnewswire.com/news-releases/duality-bio-appoints-hua-mu-as-global-chief-medical-officer-302421764.html

PR NEWSWIRE
07 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty